RegCell is a global biotechnology company pioneering therapy for autoimmune diseases. Their proprietary immune tolerance platform is based on the Nobel Prize-winning research of Co-Founder Professor Shimon Sakaguchi and is built to generate stable, epigenetically reprogrammed, antigen-specific Tregs designed to restore immune tolerance. Current autoimmune treatments broadly suppress the immune system, generally don't distinguish disease-causing immune cells from healthy ones, and don't target the underlying cause. By addressing unknown or multiple pathogenic antigens, RegCell's platform overcomes these limitations. Because RegCell's approach requires no gene engineering, it enables simplified manufacturing, enhanced safety, and greater scalability across a broad spectrum of patients. Driven by a vision to redefine self-tolerance, RegCell is committed to delivering safe, life-changing therapies for autoimmune disease.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
09/18/26	$44,000,000	Series A	Alumni Ventures Group Fast Track Initiative Global Brain Kyoto iCAP LG Technology Ventures Medical Incubator Japan Mitsui Chemicals OSAKA University Venture Capital Playground Global The University of Tokyo Edge Capital Partners	undisclosed